Systemic lupus erythematosus: modern strategies for management - a moving target

Best Practice and Research: Clinical Rheumatology

Volumn 21, Issue 6, 2007, Pages 971-987

  King, Jennifer K ^a   Hahn, Bevra H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biologics; cyclophosphamide; monoclonal antibodies; mycophenolate mofetil; systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; FOLIC ACID; FOLINIC ACID; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IBUPROFEN; IMMUNOGLOBULIN; LEFLUNOMIDE; LEUPRORELIN; MEPACRINE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRASTERONE; PREDNISOLONE; RITUXIMAB; SALICYLIC ACID DERIVATIVE; TACROLIMUS; UNINDEXED DRUG;

ACNE; ACUTE KIDNEY FAILURE; ALOPECIA; AMENORRHEA; ANEMIA; APLASTIC ANEMIA; ARTHRALGIA; ARTHRITIS; ASEPTIC MENINGITIS; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; BONE NECROSIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CASE MANAGEMENT; CATARACT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSERVATIVE TREATMENT; CUSHING SYNDROME; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GLUCOSE BLOOD LEVEL; HAIR LOSS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOPATHOGENESIS; INFECTION; INTERSTITIAL PNEUMONIA; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIPID METABOLISM; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; LOW DRUG DOSE; LUNG FIBROSIS; LUNG TOXICITY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOMA; MENSTRUATION DISORDER; MONOTHERAPY; MOUTH ULCER; MYOPATHY; NAUSEA; NEUROPATHY; OSTEOPOROSIS; OTOTOXICITY; OVARY DISEASE; PANCREATITIS; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PSYCHOSIS; RETINOPATHY; REVIEW; SIDE EFFECT; SKIN CANCER; SKIN DISCOLORATION; SKIN PIGMENTATION; SLEEP DISORDER; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; TREMOR; VOMITING; WEIGHT GAIN;

HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRACTICE GUIDELINES AS TOPIC;

EID: 36649038725     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2007.09.002     Document Type: Review

References (109)

1. Food and Drug Administration (FDA). Guidance for Industry on Systemic Lupus Erythematosus Developing Drugs for Treatment. From http://wwwfdagov/ohrms/dockets/dockets/05d0106/05d0106htm.
2. Karsh J., Kimberly R.P., Stahl N.I., et al. Comparative effects of aspirin and ibuprofen in the management of systemic lupus erythematosus. Arthritis & Rheumatism 23 12 (1980 Dec) 1401-1404
3. Wallace D.J., Metzger A.L., and Klinenberg J.R. NSAID usage patterns by rheumatologists in the treatment of SLE. The Journal of Rheumatology 16 4 (1989 Apr) 557-560
4. Ballas Z.K., and Donta S.T. Sulindac-induced aseptic meningitis. Archives of Internal Medicine 142 1 (1982 Jan) 165-166
5. Ruppert G.B., and Barth W.F. Tolmetin-induced aseptic meningitis. Journal of American Medical Association 245 1 (1981 Jan 2) 67-68
6. Weksler B.B., and Lehany A.M. Naproxen-induced recurrent aseptic meningitis. DICP 25 11 (1991 Nov) 1183-1184
7. Brezin J.H., Katz S.M., Schwartz A.B., and Chinitz J.L. Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs. The New England Journal of Medicine 301 23 (1979 Dec 6) 1271-1273
8. Shoenfeld Y., Livni E., Shaklai M., and Pinkhas J. Sensitization to ibuprofen in systemic lupus erythematosus. Journal of American Medical Association 244 6 (1980 Aug 8) 547-548
9. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. The New England Journal of Medicine 343 21 (2000 Nov 23) 1520-1528
10. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. Journal of American Medical Association 286 8 (2001 Aug 22-29) 954-959
11. Fessler B.J., Alarcon G.S., McGwin Jr. G., et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis & Rheumatism 52 5 (2005 May) 1473-1480
12. Hodis H.N., Quismorio Jr. F.P., Wickham E., and Blankenhorn D.H. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. The Journal of Rheumatology 20 4 (1993 Apr) 661-665
13. Petri M., Lakatta C., Magder L., and Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. American Journal of Medicine 96 3 (1994 Mar) 254-259
14. Wallace D.J., Metzger A.L., Stecher V.J., et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. American Journal of Medicine 89 3 (1990 Sep) 322-326
15. Edwards M.H., Pierangeli S., Liu X., et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96 12 (1997 Dec 16) 4380-4384
16. Jancinova V., Nosal R., and Petrikova M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thrombosis Research 74 5 (1994 Jun 1) 495-504
17. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Annals of the Rheumatic Diseases 66 6 (2007 Jun) 821-824
18. Bernstein H.N. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. American Journal of Medicine 75 1A (1983 Jul 18) 25-34
19. Easterbrook M. Dosage of hydroxychloroquine should be based on ideal body weight: comment on the letter by Alarcon. Arthritis & Rheumatism 48 3 (2003 Mar) 863-864 author reply 4
20. Feldmann R., Salomon D., and Saurat J.H. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 189 4 (1994) 425-427
21. Wallace D.J. Antimalarial Therapies. In: Wallace D.J.H., and BH (Eds). Dubois' Lupus Erythematosus. 7th edn (2007), Lippincott Williams & Wilkins, Philadelphia, PA 1152-1174
22. Lahita R.G., Bradlow H.L., Ginzler E., et al. Low plasma androgens in women with systemic lupus erythematosus. Arthritis & Rheumatism 30 3 (1987 Mar) 241-248
23. Straub R.H., Zeuner M., Antoniou E., et al. Dehydroepiandrosterone sulfate is positively correlated with soluble interleukin 2 receptor and soluble intercellular adhesion molecule in systemic lupus erythematosus. The Journal of Rheumatology 23 5 (1996 May) 856-861
24. Suzuki N., Suzuki T., and Sakane T. Hormones and lupus: defective dehydroepiandrosterone activity induces impaired interleukin-2 activity of T lymphocytes in patients with systemic lupus erythematosus. Annales de médecine interne 147 4 (1996) 248-252
25. Verthelyi D., Petri M., Ylamus M., and Klinman D.M. Disassociation of sex hormone levels and cytokine production in SLE patients. Lupus 10 5 (2001) 352-358
26. Chang D.M., Lan J.L., Lin H.Y., and Luo S.F. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism 46 11 (2002 Nov) 2924-2927
27. van Vollenhoven R.F., Engleman E.G., and McGuire J.L. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis & Rheumatism 38 12 (1995 Dec) 1826-1831
28. Petri M.A., Lahita R.G., Van Vollenhoven R.F., et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis & Rheumatism 46 7 (2002 Jul) 1820-1829
29. van Vollenhoven R.F., Park J.L., Genovese M.C., et al. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 8 3 (1999) 181-187
30. Pollak V.E., and Dosekun A.K. Evaluation of treatment in lupus nephritis: effects of prednisone. American Journal of kidney diseases 2 1 supplement. 1 (1982 Jul) 170-177
31. Pollak V.E., Pirani C.L., and Schwartz F.D. The natural history of the renal manifestations of systemic lupus erythematosus. The Journal of laboratory and clinical medicine 63 (1964 Apr) 537-550
32. Kirou K.A., and Boumpas D.T. Systemic Glucocorticoid Therapy in Systemic Lupus Erythematosus. Dubois' Lupus Erythematosus. 7th edn. In: Wallace D., and Hahn B.H. (Eds) (2007), Lippincott, Williams & Wilkins, Philadelphia, PA 1175-1197
33. Austin III H.A., Klippel J.H., Balow J.E., et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. The New England Journal of Medicine 314 10 (1986 Mar 6) 614-619
34. Boumpas D.T., Austin III H.A., Vaughn E.M., et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340 8822 (1992 Sep 26) 741-745
35. Gourley M.F., Austin III H.A., Scott D., et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Annals of Internal Medicine 125 7 (1996 Oct 1) 549-557
36. Illei G.G., Austin H.A., Crane M., et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Annals of Internal Medicine 135 4 (2001 Aug 21) 248-257
37. Houssiau F.A., Vasconcelos C., D'Cruz D., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis & Rheumatism 46 8 (2002 Aug) 2121-2131
38. Ballou S.P., Khan M.A., and Kushner I. Clinical features of systemic lupus erythematosus: differences related to race and age of onset. Arthritis & Rheumatism 25 1 (1982 Jan) 55-60
39. Nissenson A.R., and Port F.K. Outcome of end-stage renal disease in patients with rare causes of renal failure. III. Systemic/vascular disorders. The Quarterly Journal of medicine 74 273 (1990 Jan) 63-74
40. Ward M.M., and Studenski S. Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences. Archives of Internal Medicine 150 4 (1990 Apr) 849-853
41. Dooley M.A., Hogan S., Jennette C., and Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney International 51 4 (1997 Apr) 1188-1195
42. Houssiau F.A., Vasconcelos C., D'Cruz D., et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis & Rheumatism 50 12 (2004 Dec) 3934-3940
43. Chan T.M., Li F.K., Tang C.S., et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. The New England Journal of Medicine 343 16 (2000 Oct 19) 1156-1162
44. Hu W., Liu Z., Chen H., et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chinese Medical Journal 115 5 (2002 May) 705-709
45. Contreras G., Pardo V., Leclercq B., et al. Sequential therapies for proliferative lupus nephritis. The New England Journal of Medicine 350 10 (2004 Mar 4) 971-980
46. Ginzler E.M., Dooley M.A., Aranow C., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. The New England Journal of Medicine 353 21 (2005 Nov 24) 2219-2228
47. Chan T.M., Tse K.C., Tang C.S., et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. Journal of the American Society of Nephrology 16 4 (2005 Apr) 1076-1084
48. Grootscholten C., Bajema I.M., Florquin S., et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis & Rheumatism 56 3 (2007 Mar) 924-937
49. Chan T.M., Tse K.C., Tang C.S., et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 14 4 (2005) 265-272
50. Cush J.J., KA, and Stein C.M. Rheumatology Diagnosis and Therapeutics. 2nd edn (2005), Lippincott Williams & Wilkins, Philadelphia, PA
51. Bertsias G.K., Ioannidis J.P., Boletis J., et al. EULAR recommendations for the management of Systemic Lupus Erytematosus (SLE) Report of a Task Force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)*. Annals of the Rheumatic Diseases (2007 May 15)
52. Barile-Fabris L., Ariza-Andraca R., Olguin-Ortega L., et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Annals of the Rheumatic Diseases 64 4 (2005 Apr) 620-625
53. Mok C.C., Lau C.S., Chan E.Y., and Wong R.W. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome. The Journal of Rheumatology 25 3 (1998 Mar) 467-473
54. Stojanovich L., Stojanovich R., Kostich V., and Dzjolich E. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus 12 1 (2003) 3-7
55. Neuwelt C.M., Lacks S., Kaye B.R., et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. American Journal of Medicine 98 1 (1995 Jan) 32-41
56. Lewis E.J., Hunsicker L.G., Lan S.P., et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. The New England Journal of Medicine 326 21 (1992 May 21) 1373-1379
57. Zhou H.Q., Leng X.M., and Zhang F.C. [Neuropsychiatric manifestations in systemic lupus erythematosus and the treatment of intrathecal methotrexate plus dexamethasone]. Zhonghua Yi Xue Za Zhi 86 11 (2006 Mar 21) 771-774
58. Carneiro J.R., and Sato E.I. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. The Journal of Rheumatology 26 6 (1999 Jun) 1275-1279
59. Rahman P., Humphrey-Murto S., Gladman D.D., and Urowitz M.B. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. The Journal of Rheumatology 25 2 (1998 Feb) 243-246
60. McCune W., Marder W., and Riskalla M. Immunosuppressive Drug Therapy. In Dubois' Lupus Erythematosus (2007), Lippincott Williams and Wilkins, Philadelphia, PA
61. Petri M. Arava in Lupus. American College of Rheumatology 65th Annual Scientific Meeting. Arthritis and Rheumatism 44 (2001) S1364
62. Sato E.I. Methotrexate therapy in systemic lupus erythematosus. Lupus 10 3 (2001) 162-164
63. Morton S.J., and Powell R.J. An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use. Annals of the Rheumatic Diseases 59 6 (2000 Jun) 487-489
64. Wallace D. Additional Therapies Used in the Management of Lupus. Dubois' Lupus Erythematosus. 7th edn. In: Wallace D.J., and Hahn B.H. (Eds) (2007), Lippincott Williams and Wilkins, Philadelphia, PA
65. Kreuter A., Gambichler T., Breuckmann F., et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. Journal of the American Academy of Dermatology 51 3 (2004 Sep) 407-410
66. Lampropoulos C.E., Sangle S., Harrison P., et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 43 11 (2004 Nov) 1383-1385
67. Anonymous. http://www.fda.gov/fdac/departs/2006/206_upd.html#eczema. Journal [serial on the Internet]. Last accessed April 2006. Date.
68. Wallace D.J. What's new in the management of lupus since 2000?. Journal of Clinical Rheumatology 12 6 (2006 Dec) 307-313
69. Sontheimer R.D., and MD. Lupus - Specific Skin Disease (Cutaneous LE). 7th ed. In: Wallace D., and HB (Eds) (2006), Lippincott Williams & Wilkins, Philadelphia, PA
70. Leandro M.J., Edwards J.C., Cambridge G., et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis & Rheumatism 46 10 (2002 Oct) 2673-2677
71. Looney R.J., Anolik J.H., Campbell D., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis & Rheumatism 50 8 (2004 Aug) 2580-2589
72. Sfikakis P.P., Boletis J.N., and Tsokos G.C. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Current Opinion In Rheumatology 17 5 (2005 Sep) 550-557
73. Leandro M.J., Cambridge G., Edwards J.C., et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44 12 (2005 Dec) 1542-1545
74. Ng K.P., Leandro M.J., Edwards J.C., et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Annals of the Rheumatic Diseases 65 7 (2006 Jul) 942-945
75. Tokunaga M., Saito K., Kawabata D., et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Annals of the Rheumatic Diseases 66 4 (2007 Apr) 470-475
76. Sfikakis P.P., Boletis J.N., Lionaki S., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis & Rheumatism 52 2 (2005 Feb) 501-513
77. Ng K.P., Cambridge G., Leandro M.J., et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Annals of the Rheumatic Diseases 66 9 (2007 Sep) 1259-1262
78. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. The New England Journal of Medicine 350 25 (2004 Jun 17) 2572-2581
79. Vallerskog T., Gunnarsson I., Widhe M., et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clinical Immunology 122 1 (2007 Jan) 62-74
80. Alert F., Rituximab (marketed as Rituxan) Information. 12/18/2006 [updated 12/18/2006; cited]; Available from: http://www.fda.gov/cder/drug/infosheets/hcp/rituximab.pdf.
81. Dorner T., Kaufmann J., Wegener W.A., et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Research & Therapy 8 3 (2006) R74
82. Human Genome Sciences. Available at: http://www.hgsi.com/products/LSB.html, editor.
83. Furie R., SW, Ginzler E., et al. Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of lymphostat-B (human monocloncal antibody to BLyS) in SLE patients. Arthritis & Rheumatism 48 9 supplement (2003) S377
84. Furie R., LJ, Merrill J.T., et al. Belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLys]) improves or stabilizes SLE activity in a multicenter phase 2 trial. Arthritis and Rheumatism 54 9 supplement (2006) S28
85. In: Silvermann G.J., and aKK (Eds). Latest Advances in B-Cell Science (April 20, 2007)
86. Stohl W., WD, Merrill J.T., et al. Changes in circulating B-cell counts, autoantibody levels and immunoglobulins that associate with therapeutic responsiveness in SLE to BLyS protein antagonism by belimumab. Arthritis & Rheumatism 54 9 supplement (2006) S780
87. Dall'Era M CE GM, et al. Trial of atacicept in patients with systemic lupus erythematosus. Abstract L19. ACR/ARHP Annual Scientific Meeting. November 2006.
88. Genovese M.C., Becker J.C., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. The New England Journal of Medicine 353 11 (2005 Sep 15) 1114-1123
89. Westhovens R., Cole J.C., Li T., et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 45 10 (2006 Oct) 1238-1246
90. Daikh D.I., and Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. Journal of Immunology 166 5 (2001 Mar 1) 2913-2916
91. Kalunian K.C., Davis Jr. J.C., Merrill J.T., et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism 46 12 (2002 Dec) 3251-3258
92. Boumpas D.T., Furie R., Manzi S., et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis & Rheumatism 48 3 (2003 Mar) 719-727
93. Freedman J.E. CD40 ligand-assessing risk instead of damage?. The New England Journal of Medicine 348 12 (2003 Mar 20) 1163-1165
94. Alarcon-Segovia D., Tumlin J.A., Furie R.A., et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis & Rheumatism 48 2 (2003 Feb) 442-454
95. Furie R.A., Cash J.M., Cronin M.E., et al. Treatment of systemic lupus erythematosus with LJP 394. The Journal of Rheumatology 28 2 (2001 Feb) 257-265
96. Mosca M., Baldini C., and Bombardieri S. LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus. Expert Opinion on Pharmacotherapy 8 6 (2007 Apr) 873-879
97. Furie R. Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus. Rheumatic Diseases Clinics of North Americas 32 1 (2006 Feb) 149-156 x
98. Teva Pharmaceuticals. Available at: http://www.tevapharm.com/research/products_ai.asp
99. Aringer M., Graninger W.B., Steiner G., and Smolen J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis & Rheumatism 50 10 (2004 Oct) 3161-3169
100. Aringer M., Steiner G., Graninger W.B., et al. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis & Rheumatism 56 1 (2007 Jan) 274-279
101. Debandt M., Vittecoq O., Descamps V., et al. Anti-TNF-alpha-induced systemic lupus syndrome. Clinical Rheumatology 22 1 (2003 Feb) 56-61
102. Favalli E.G., Sinigaglia L., Varenna M., and Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 11 11 (2002) 753-755
103. Baechler E.C., Batliwalla F.M., Karypis G., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proceedings of the National Academy of Sciences of the United States of America 100 5 (2003 Mar 4) 2610-2615
104. Feng X., Wu H., Grossman J.M., et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis & Rheumatism 54 9 (2006 Sep) 2951-2962
105. Braun-Moscovici Y., and Furst D.E. Stem cell therapy in scleroderma. Current Opinion In Rheumatology 14 6 (2002 Nov) 711-716
106. Burt R.K., Traynor A., Statkute L., et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. Journal of American Medical Association 295 5 (2006 Feb 1) 527-535
107. Jayne D., Passweg J., Marmont A., et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13 3 (2004) 168-176
108. Petri M., Jones R.J., and Brodsky R.A. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis & Rheumatism 48 1 (2003 Jan) 166-173
109. Petri M., Brodsky R., Jones R.J., et al. Cyclophosphamide Vs. Monthly (NIH) Cyclophosphaide: Final Results. Arthritis and Rheumatism 54 9 (2006) S444 (abstract 1038)